Skip to main content

Managing costs associated with cell and gene therapy

cell and gene therapy

Employers continue to struggle with controlling rising healthcare costs and providing employees with affordable and quality care options. Of particular concern are the high costs associated with specialty drugs, including treatments like cell and gene therapy.

The specialty drug industry has grown from a few available drugs in the 1990s to more than 300 specialty drugs today. Specialty drugs are the fastest-growing expense for most employer-sponsored health plans. As these treatments become more widely available, employers will likely be forced to address even higher specialty drug costs.

The recent rise of cell and gene therapy may create even more concern for employers. These treatments typically range from $250,000 to $3.5 million per individual. While CGT is currently limited to a handful of orphan drugs and extremely rare conditions, this is expected to change in the next few years.

Investment in regenerative medicine has grown 16% in three years, hitting a record high of $23.1 billion in 2021. As investment in this market continues to grow, the Business Research Company expects it to reach $34.31 billion in 2030. Therefore, without effective solutions in place, employers may be forced to contend with extreme and, in some cases, unsustainable medical costs.

This article explores strategies for managing the high costs associated with CGT.

What is cell and gene therapy?

CGT is a treatment that modifies a patient’s genetic code to treat or cure specific diseases. This is accomplished by adjusting a patient’s genetic code, replacing a disease-causing gene or introducing a new or modified gene to treat the disease. Patients generally receive CGT through injection or infusion in a specialty setting. These treatments have the potential to enhance patient care and outcomes, but they are very expensive.

Currently, there’s an urgency to bring CGT to an even wider market because these treatments offer hope to individuals suffering from rare and debilitating diseases. However, these treatments also create massive affordability challenges for employers. Therefore, the high costs associated with these therapies require employers to examine their coverage decisions.

Why is CGT so expensive?

One of the main reasons CGT is extremely costly is that developing and manufacturing these treatments takes a significant amount of time and resources. Developing CGTs can cost over $5 billion, more than five times the average cost of developing traditional drugs. Additionally, these treatments are manufactured using manual processes and are typically made in small quantities, which limits production capability.

As a result, the current demand for CGT is outpacing manufacturing capacity. As of 2022, about 75,000 patients were eligible for CGT, costing more than $15 billion. That number is expected to grow to 100,000 patients over the next three years and cost more than $25 billion. The increased demand in CGT is forcing therapy developers to outsource treatment production and manufacturing. This is often very complex, resulting in increased production time and costs.

Another reason CGT is so expensive is these treatments are not mass-produced like traditional biologicals and serve only a small patient population. Additionally, since this is a relatively new industry, there is a shortage of skilled workers to produce and manufacture the treatments, driving up manufacturers’ labor costs.

To address these issues, the CGT industry is trying to automate more of the production and manufacturing processes to improve overall efficiency, which could lead to faster, safer and more cost-effective CGT production. Regulatory considerations, longer inpatient stays and the use of specialty pharmacies are additional reasons CGT costs more than traditional treatments.

What can employers do to manage CGT costs?

Employers already struggling to control the rising costs of specialty drugs should not put off planning and implementing strategies to manage CGT costs until it’s too late. While the number of available CGTs is currently modest, the U.S. Food and Drug Administration estimates it could be approving between 10 and 20 annually by 2025. So, even if employers are not dealing with the costs of CGT now, they will soon.

The best strategies for managing CGT costs will likely vary depending on the organization’s needs, size and demographics; however, embracing a combination of strategies will likely be the most effective approach. Here are three strategies employers can consider for managing CGT costs:

  1. Managed access: Some employers have started to use independent third parties when prior authorization is required for expensive specialty drugs and treatment.
  2. Exclusions: Some employers have limited or outright excluded plan coverage of certain specialty drugs, including CGT. However, limiting or excluding CGT from health plan coverage may result in compliance risks.
  3. Nontraditional payment models: CGT operates very differently from traditional treatments. CGT treatments are generally administered once or twice over a patient’s lifetime. With traditional treatments, a drug is administered and paid for over time as the prescription is filled, and patients receive the health benefits incrementally. With CGT, payment occurs upfront and the patient experiences health benefits over time.

    As a result, employers can explore nontraditional payment models offered by insurance and pharmaceutical companies to help offset treatment costs. For example, some insurance companies have implemented programs to mitigate CGT’s upfront costs. Cigna allows employers to contribute less than $1 per member per month (the patient would not have to pay out of pocket for the treatment), and CVS Health offers financial protection solutions, such as stop-loss coverage and installment payments.

Next steps: Contact us today

CGT shows immense potential for improving patient outcomes. As the number of available CGTs continues to grow, employers will need to consider creative solutions to manage the costs of these therapies. Understanding CGT and its potential impact on healthcare costs allows employers to better prepare and implement effective cost-mitigating strategies.

Reach out to HANYS Benefit Services for more information on managing healthcare costs. Our dedicated team of experts is here to help you with all of your retirement and employee benefit needs.

This Benefits Insights is not intended to be exhaustive nor should any discussion or opinions be construed as professional advice. © 2023 Zywave, Inc. All rights reserved.

Popular posts from this blog

SECURE 2.0 Discussion Series: Session One

SECURE 2.0 provisions: What we know and what’s still up in the air The SECURE 2.0 Act, signed into law in late December 2022, has factored heavily in retirement industry discourse since the final legislation was published. As with any legislation of this depth and breadth, there’s a lot to digest and the industry takes time to adjust. Our team of experienced advisors recently met to discuss some of the more nuanced provisions of the legislation, such as changes to Roth contributions, and what they could mean for plan sponsors. Panel participants included the following HBS team members: Noah Buck, Christina Bauer-Dobias, Sean Bayne, Vincent Bocchinfuso and Kathleen Coonan. Highlights of our panel’s conversation below should serve to help guide plan sponsor thinking. On Roth employer contributions NB – In addition to deferring pre-tax or Roth, plan sponsors can now allow employer contributions to be classified as Roth, is that right? VB – Correct. This is immediately available to plan s

COVID-19: Retirement and Benefit Plan Resources

As the COVID-19 crisis continues to unfold, we are closely monitoring news and updates from top sources. We’ll be updating this section as new developments unfold. Here are several key articles and links to help plan sponsors and administrators navigate the COVID-19 impact to retirement and benefit plans: Retirement Plans 4 Key CARES Act Provisions for Retirement Plan Sponsors Markets React to Coronavirus   Important Considerations for Retirement Plan Sponsors during the Coronavirus Pandemic In Fed We Trust Participant Education Services: Timely Help from a Safe Distance CRDs 100% Taxable for New York State and Local Income Tax Purposes in 2020 IRS Permits Remote Notarization of Participant Elections   Employee Benefits CARES Act Expands Health Coverage Rules Understanding the Historic $2 Trillion Stimulus Package Employee Compensation and Benefits During Closures and Furloughs DOL Clarifies Exemptions to Coronavirus Paid Leave Laws Small Business Exemption to

SECURE 2.0 Discussion Series: Session Two

The retirement industry has been buzzing since the SECURE 2.0 Act was signed into law last December. This new, comprehensive legislation has sparked a lot of discussion. As with any major reform, it will take time for the industry to fully adapt and understand all its implications. Following our April 11 webinar on the first three months of the industry’s response, our team reconvened to discuss some of what we have heard from our client and vendor partners and to respond to some of the great questions we heard from attendees. Panel participants included the following HBS team members: Noah Buck, Christina Bauer-Dobias, Sean Bayne, Vincent Bocchinfuso and Kathleen Coonan. The Discussion SB – Throughout the webinar, I wanted to stress two things: 1) confusion about where to start and what is expected from plan sponsors is normal; and 2) even more than three months in, this is a developing situation and people should expect changes as time goes on. With those in mind, engagement through